FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313334095> ?p ?o ?g. }

• W4313334095 endingPage "506" @default.
• W4313334095 startingPage "499" @default.
• W4313334095 abstract "To date, no specific therapies have been approved for immunoglobulin A nephropathy (IgAN) treatment. Telitacicept is a fusion protein composed of transmembrane activator and calcium-modulating cyclophilin ligand interactor and fragment crystallizable portion of immunoglobulin G (IgG), which neutralizes the B lymphocyte stimulator and a proliferation-inducing ligand.This phase 2 randomized placebo-controlled trial aimed to evaluate the efficacy and safety of telitacicept in patients with IgAN. Participants with an estimated glomerular filtration rate (eGFR) >35 ml/min per 1.73 m2 and proteinuria ≥0.75 g/d despite optimal supportive therapy, were randomized 1:1:1 to receive subcutaneous telitacicept 160 mg, telitacicept 240 mg, or placebo weekly for 24 weeks. The primary end point was the change in 24-hour proteinuria at week 24 from baseline.Forty-four participants were randomized into placebo (n = 14), telitacicept 160 mg (n = 16), and telitacicept 240 mg (n = 14) groups. Continuous reductions in serum IgA, IgG, and IgM levels were observed in the telitacicept group. Telitacicept 240 mg therapy reduced mean proteinuria by 49% from baseline (change in proteinuria vs. placebo, 0.88; 95% confidence interval, -1.57 to -0.20; P = 0.013), whereas telitacicept 160 mg reduced it by 25% (-0.29; 95% confidence interval, -0.95 to 0.37; P = 0.389). The eGFR remained stable over time. Adverse events (AEs) were similar in all groups. Treatment-emergent AEs were mild or moderate, and no severe AEs were reported.Telitacicept treatment led to a clinically meaningful reduction in proteinuria in patients with IgAN in the present phase 2 clinical trial. This effect is indicative of a reduced risk for future kidney disease progression." @default.
• W4313334095 created "2023-01-06" @default.
• W4313334095 creator A5020579375 @default.
• W4313334095 creator A5021170475 @default.
• W4313334095 creator A5022797907 @default.
• W4313334095 creator A5024519095 @default.
• W4313334095 creator A5028863621 @default.
• W4313334095 creator A5033471083 @default.
• W4313334095 creator A5033632697 @default.
• W4313334095 creator A5037172130 @default.
• W4313334095 creator A5041861176 @default.
• W4313334095 creator A5043523517 @default.
• W4313334095 creator A5045806770 @default.
• W4313334095 creator A5048018294 @default.
• W4313334095 creator A5055139554 @default.
• W4313334095 creator A5062229369 @default.
• W4313334095 creator A5066863522 @default.
• W4313334095 creator A5069849278 @default.
• W4313334095 creator A5074414128 @default.
• W4313334095 creator A5075158591 @default.
• W4313334095 creator A5077423550 @default.
• W4313334095 creator A5077679832 @default.
• W4313334095 creator A5082858469 @default.
• W4313334095 creator A5087424328 @default.
• W4313334095 creator A5089081895 @default.
• W4313334095 creator A5091218208 @default.
• W4313334095 date "2023-03-01" @default.
• W4313334095 modified "2023-10-11" @default.
• W4313334095 title "Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria" @default.
• W4313334095 cites W1589968846 @default.
• W4313334095 cites W1977053325 @default.
• W4313334095 cites W1982924102 @default.
• W4313334095 cites W2018337150 @default.
• W4313334095 cites W2025680630 @default.
• W4313334095 cites W2034185130 @default.
• W4313334095 cites W2048162256 @default.
• W4313334095 cites W2058154849 @default.
• W4313334095 cites W2059839808 @default.
• W4313334095 cites W2096977413 @default.
• W4313334095 cites W2150978602 @default.
• W4313334095 cites W2427125740 @default.
• W4313334095 cites W2557141247 @default.
• W4313334095 cites W2600347335 @default.
• W4313334095 cites W2801776960 @default.
• W4313334095 cites W2921779970 @default.
• W4313334095 cites W2964038660 @default.
• W4313334095 cites W2965853783 @default.
• W4313334095 cites W3011996627 @default.
• W4313334095 cites W3046339311 @default.
• W4313334095 cites W3092339924 @default.
• W4313334095 cites W3119665282 @default.
• W4313334095 cites W3182427063 @default.
• W4313334095 cites W3182600246 @default.
• W4313334095 cites W3196430201 @default.
• W4313334095 cites W3198766355 @default.
• W4313334095 cites W3200414796 @default.
• W4313334095 cites W3200479416 @default.
• W4313334095 cites W4210480986 @default.
• W4313334095 cites W4210849595 @default.
• W4313334095 cites W4211021420 @default.
• W4313334095 cites W4281567558 @default.
• W4313334095 doi "https://doi.org/10.1016/j.ekir.2022.12.014" @default.
• W4313334095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36938094" @default.
• W4313334095 hasPublicationYear "2023" @default.
• W4313334095 type Work @default.
• W4313334095 citedByCount "5" @default.
• W4313334095 countsByYear W43133340952023 @default.
• W4313334095 crossrefType "journal-article" @default.
• W4313334095 hasAuthorship W4313334095A5020579375 @default.
• W4313334095 hasAuthorship W4313334095A5021170475 @default.
• W4313334095 hasAuthorship W4313334095A5022797907 @default.
• W4313334095 hasAuthorship W4313334095A5024519095 @default.
• W4313334095 hasAuthorship W4313334095A5028863621 @default.
• W4313334095 hasAuthorship W4313334095A5033471083 @default.
• W4313334095 hasAuthorship W4313334095A5033632697 @default.
• W4313334095 hasAuthorship W4313334095A5037172130 @default.
• W4313334095 hasAuthorship W4313334095A5041861176 @default.
• W4313334095 hasAuthorship W4313334095A5043523517 @default.
• W4313334095 hasAuthorship W4313334095A5045806770 @default.
• W4313334095 hasAuthorship W4313334095A5048018294 @default.
• W4313334095 hasAuthorship W4313334095A5055139554 @default.
• W4313334095 hasAuthorship W4313334095A5062229369 @default.
• W4313334095 hasAuthorship W4313334095A5066863522 @default.
• W4313334095 hasAuthorship W4313334095A5069849278 @default.
• W4313334095 hasAuthorship W4313334095A5074414128 @default.
• W4313334095 hasAuthorship W4313334095A5075158591 @default.
• W4313334095 hasAuthorship W4313334095A5077423550 @default.
• W4313334095 hasAuthorship W4313334095A5077679832 @default.
• W4313334095 hasAuthorship W4313334095A5082858469 @default.
• W4313334095 hasAuthorship W4313334095A5087424328 @default.
• W4313334095 hasAuthorship W4313334095A5089081895 @default.
• W4313334095 hasAuthorship W4313334095A5091218208 @default.
• W4313334095 hasBestOaLocation W43133340951 @default.
• W4313334095 hasConcept C126322002 @default.
• W4313334095 hasConcept C126894567 @default.
• W4313334095 hasConcept C134018914 @default.
• W4313334095 hasConcept C142724271 @default.
• W4313334095 hasConcept C159641895 @default.

• next